Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied? - Wikidata - wikimedia - TriplyDB

Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?

Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?

http://www.wikidata.org/entity/Q48081904

about

International comparison of experience-based health state values at the population level.Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.Multimorbidity in primary care: protocol of a national cross-sectional study in Switzerland Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments.EQ-5D in Central and Eastern Europe: 2000-2015.A Comparison of Iran and UK EQ-5D-3L Value Sets Based on Visual Analogue Scale.The impact of low back pain on health-related quality of life in old age: results from a survey of a large sample of Swiss elders living in the community.

P2860

Q33883700-64D08441-43EC-4D98-89B8-7044164D4BE6 Q35606843-D653F694-C7C8-4B98-B1C8-434EF829642D Q36258830-0BAD89BB-D2C5-4352-A287-874FD408116A Q38710744-854F8328-D6CB-40FA-BA6F-D0C26482D9F9 Q38912637-C387BC16-2695-4D6C-886F-CAD18ADAB3B6 Q40081537-04E3BE12-F910-4B6B-A4E0-A210C2183EB6 Q48106673-E0D4DB15-EC59-4A85-B7BC-4A9AE6058414

P2860

Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?

http://www.wikidata.org/entity/Q48081904

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?

@en

Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?

@nl

type

label

Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?

@en

Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?

@nl

prefLabel

Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?

@en

Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?

@nl

P1433

Q48081904-52EB7A78-A1B0-4427-93D9-54B662D7FC63

P1476

Q48081904-8F916D88-CE8F-456C-8B82-1A7C987A4F7F

P2093

Q48081904-17792E6C-FAE9-4832-A24E-D814590B13C1

Q48081904-77EA49EE-AC6E-4E06-AC59-79CA2D036A19

P2860

Q48081904-079E079D-03AA-48DD-BD42-43FD8D3C1F59

Q48081904-0F7652F2-64B7-4DCD-90A3-77D8055746A3

Q48081904-2001A54C-BEA7-4D0F-9BC6-F5A46D4FCD31

Q48081904-44CE41BB-E097-411D-8010-34082D82684D

Q48081904-5C4AF00C-FCBE-41A4-B02C-378FC3133934

Q48081904-619EA280-1B20-4A70-8A51-A629F5C0FE20

Q48081904-68A7D6C1-E0CE-4986-9DF0-29BCF9F3D49A

Q48081904-8F5F277B-CA55-4F9E-833C-38B730D19DEF

Q48081904-9B7F9AE7-0B67-4DBA-99F6-26A1A456CF83

Q48081904-AC1D4A72-9FA9-43D0-B0DF-F1C055986FBC

P2888

Q48081904-8BD4B48B-9E0B-49F9-9D43-65FC87D78B7D

P304

Q48081904-8986CA69-4448-4598-8DD8-C8159F55B1DF

P31

Q48081904-194419EB-9EDE-4203-914E-A08194352587

P356

Q48081904-9FA56391-0B7B-433F-865D-3F97B9731F46

P433

Q48081904-06260AB5-FBCB-4DDD-9826-47524B831979

P478

Q48081904-606B339E-8B5C-4D46-A922-0D2EED312E85

P50

Q48081904-668AFAC9-7B1B-4FA5-8AF2-80F3A04EB885

Q48081904-7EDF5E5D-8437-48F2-8673-EADC45D483B4

Q48081904-CFA15BCA-7CBC-4BF4-9064-1FD9249AE86A

P577

Q48081904-B0DC2609-17AE-4B48-952A-ECC6AF31368C

P5875

Q48081904-D9FD5728-FBA0-4D09-90CF-CD8E6A3C8119

P698

Q48081904-55DCF4F8-0993-49B4-A0D6-9D7610C164E4

P356

S40273-014-0151-0

P1433

PharmacoEconomics

P1476

Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?

@en

P2093

Bernhard C Pestalozzi

http://www.w3.org/2001/XMLSchema#string

Thomas Szucs

http://www.w3.org/2001/XMLSchema#string

P2860

EQ-5D: a measure of health status from the EuroQol Group.

Correspondence between EQ-5D health state classifications and EQ VAS scores.

Decomposing cross-country differences in quality adjusted life expectancy: the impact of value sets.

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer.

Does the correspondence between EQ-5D health state description and VAS score vary by medical condition?

International comparisons in valuing EQ-5D health states: a review and analysis.

Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.

Preliminary findings of an investigation into the relationship between national culture and EQ-5D value sets.

Valuing EQ-5D using time trade-off in France.

Utilities of the EQ-5D: transferable or not?

P2888

s40273-014-0151-0

P304

591-599

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40273-014-0151-0

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Matthias Schwenkglenks

Klazien Matter-Walstra

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261139831

http://www.w3.org/2001/XMLSchema#string

P698

24671924

http://www.w3.org/2001/XMLSchema#string